We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnostics Company Provides Clinical Interpretation of Genomics Data

By LabMedica International staff writers
Posted on 30 Jan 2013
A diagnostics company was launched to provide rapid, accurate, and turnkey clinical interpretation of genomics data at the point-of-care (POC). More...
The next phase of genomics-based medicine will provide clinicians with the tools they need to make faster, more precise and cost-saving decisions.

SV Bio’s (Foster City, CA, USA) turnkey genomics interpretation services query the patient’s genome at the POC and provide the biologic data in a concise, actionable report that medical generalists and specialists can easily use as a decision support tool. The platform fits into current clinical workflows and is able to take data from any next generation sequencer and determine, with clinical grade sensitivity and specificity, which genetic variants within a patient’s DNA sequence are influencing a disease or condition.

Many patients have already been helped by SV Bio diagnostic services. One case involved a family with two affected children who were initially thought to have autism spectrum disorder due to their language regression, IQ drops, and seizures at two years of age. Subsequent neurodegenerative decline puzzled physicians at leading medical institutions, and triggered a multiyear odyssey of clinical workups and focused genetic testing. Ultimately, the physicians turned to SV Bio, where the patient genomes were sequenced and the underlying genetic mutation in a gene named TPP1 was uncovered immediately.

The gene defect causes the rare disease late-infantile neuronal ceroid lipofuscinosis that is fatal by 8 years of age. The mutation was verified biochemically to be causative of the disorder, and allowed the children to gain access to a clinical trial that has shown promising results at halting the progression of the disease—a trial to which they would never have turned for a solution to a fatal disease in the absence of a specific molecular diagnosis.

“The transition is occurring very rapidly nowadays from genomics as a science to genomics as a key driver of clinical medicine and decision-making at the bedside,” noted Dietrich Stephan, PhD, SV Bio founder and CEO.

SV Bio is currently providing diagnostic testing services to physicians and centers of excellence for all heritable genetic conditions. These services include testing single genes and bundled gene sets for disorders that are genetically heterogeneous and for which the causative genes are known. In addition, testing of the entire genome is available for mystery illnesses or in cases where other diagnostic companies could not return a definitive result because the causative gene is not known, or in cases where a variant was detected but could not be classified as causative. SV Bio uses classification technology that provides precision of pathogenicity prediction for variants not been seen before—increasing sensitivity when coupled with the highest quality next-generation
sequencing of the entire genome.

Related Links:
SV Bio


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.